• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Cellular products in Russia: where we stand?

27.03.2017/in News /by X7 Research

The global market for stem cells has been estimated at 12 billion US dollars in 2016 and is projected to reach 26.6 billion by 2021, with annual growth rate of 13,7% during the forecast period 2016 to 2021. Several factors, though, restrain market growth. Such products cost very high, moreover, ethical issues arise about them frequently as well as regulatory complications develop. Also, the clinical efficacy of cellular products is still questionable for today – for example, in recently completed MASTERS trial multipotent adult progenitor cells were proven ineffective in stroke recovery.

In Russia, the industry of cellular product is still in the early development phase because the use of cellular products is anecdotal and the purpose is mostly scientific. Recently, however, regulatory authorities in Russia started to develop the legislative basis for cellular products.

On January 1st, 2017 law N 180-ФЗ regarding the medical use of cellular products came into force. There is a void of questions and imperfections in this law, experts say. Pavel Vorobiev, head of Moscow City Scientific Society of Internal Medicine Physicians criticizes the new law as proposed definition of cellular product is very vague. Mr. Vorobiev also states that the law opens a huge way for bureaucracy and does not provide any benefits for industry or science. Law N 180-ФЗ virtually mirrors law 61-ФЗ (on the circulation of medical products for human use), but cells are different from other medications and specific approach to them is most certainly needed.

For example, the new law implies the concept of the international non-proprietary name onto cellular products. Hypothetically, bone particles grown from bone progenitor cells could have international non-proprietary name “mesenchymal cell line” and trade name “bone particle for heel”, which doesn’t make any sense. Expert considers that new law will not promote cellular products development in Russia, but, on the contrary, many laboratories will have to stop their work under bureaucratic pressure.

Nevertheless, recently Russian Ministry of Health opened brand new draft laws regarding approval of clinical trials of cellular products, cellular sample collection and quality control, expert consultation on cellular products and considering the order of import of cellular product for the treatment of individual subjects for public discussion. A bunch of draft documents has also been released earlier this year.

Such an active discussion gives hope that when all practical issues will be considered market of cellular products in Russia will follow general trend to growth and development.

 

Sources:

https://www.mordorintelligence.com/industry-reports/global-stem-cell-research-market-growth-trends-forecasts-industry

http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30046-7/fulltext

http://regulation.gov.ru/

http://www.pharmvestnik.ru/publs/lenta/v-rossii/ekspert-nachalsja-protsess-totaljnogo-unichtozhenija-otrasli-kletochnyx-texnologij.html#.WNYI9xLyhR1

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 3 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Russian Roszdravnadzor and Ministry of Health participate in international medicinal... Our decisive “No” to unproven interventions – British Medical Journal...
Scroll to top